ReBlood Rx
PrivateLast Round
Grant
Jan 1, 2026
Total Funding Raised
$402,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ReBlood Rx operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Grant round in January 2026.
ReBlood Rx is a biotechnology company that develops hemoglobin-based oxygen carriers (HBOCs) to provide safe and efficient oxygen delivery solutions for medical emergencies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Defense Tech
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReBlood Rx Comparables
Compare ReBlood Rx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VirTech Bio | 91% | |
| KaloCyte, Inc. | 84% | |
| OxyVita Inc. | 80% |
For institutional investors. Book with your work email.
ReBlood Rx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 1, 2026 | ||||
| Seed | Aug 4, 2025 | ||||
| Grant | Aug 4, 2025 | ||||
| Accelerator | Aug 19, 2024 | ||||
| Grant | Jul 1, 2024 |
For institutional investors. Book with your work email.
ReBlood Rx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DIANA | Grant |
| 757 Collab | Accelerator |
| 757 Accelerate | Accelerator |
| rpv | Seed |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 30, 2026
Monthly visitors increased 680% MoM, from 54 to 421.
- Jan 1, 2026
$107K grant received from DIANA.
For institutional investors. Book with your work email.
ReBlood Rx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ReBlood Rx's valuation, stock price, and market status.
Is ReBlood Rx a public or private company?
ReBlood Rx is a private company.
What is the current stock price of ReBlood Rx?
ReBlood Rx is a private company, so its shares have no public market price. Caplight tracks ReBlood Rx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ReBlood Rx worth (valuation)?
Valuation information for ReBlood Rx is not publicly available.
Can I buy ReBlood Rx stock?
ReBlood Rx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ReBlood Rx's last funding round?
ReBlood Rx's most recent funding round was Grant on January 1, 2026.
Who are the main investors in ReBlood Rx?
Key investors in ReBlood Rx include DIANA, 757 Collab, 757 Accelerate, rpv, National Science Foundation.
Will ReBlood Rx IPO soon?
No public IPO plans have been announced for ReBlood Rx.
How can I track ReBlood Rx secondary market activity?
Caplight tracks bids, offers, and trades in ReBlood Rx's shares on secondary markets.